Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Tonix Pharmaceuticals Holding / Equity Bottom-Up

<ul><li>On August 15, 2025, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the U.S. Food and Drug Administration (FDA) approved Tonmya (cyclobenzaprine HCl sublingual tablet) for the treatment of fibromyalgia.</li><li>Tonmya is the first FDA approved therapy for fibromyalgia in over 15 years.</li><li>The approval was based in part on data from two double blind, placebo controlled Phase 3 trials of nearly 1,000 patients in total that showed Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks, the primary endpoint.</li></ul>

On August 15, 2025, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the U.S. Food and Drug Administration (FDA) approved Tonmya (cyclobenzaprine HCl sublingual tablet) for the treatment of fibromyalgia.Tonmya is the first FDA approved therapy for fibromyalgia in over 15 years.The approval was based in part on data from two double blind, placebo controlled Phase 3 trials of nearly 1,000 patients in total that showed Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks, the primary endpoint.

Tonix Pharmaceuticals Holding

TNXP: Tonmya Approved by FDA